BL Pharmtech Corp. (KOSDAQ:065170)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,720.00
+625.00 (29.83%)
At close: Sep 11, 2026

BL Pharmtech Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3,0906,5068,80624,52522,52384,440
Revenue Growth
-64.20%-26.12%-64.10%8.89%-73.33%28.54%
Gross Profit
1,1463,6925,92113,56112,72221,073
Operating Income
-1,205-2,032-4,345-7,119-4,789-3,595
Net Income
-16,003-16,778-5,706-148.85-13,903-20,211
Earnings Per Share
-598.61-628.85-214.00-5.58-520.90-767.32
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
5,7897,1513,86413,2075,52422,752
Total Debt
3,4515,0426,1004,26242,70641,894
Net Cash (Debt)
2,3382,110-2,2368,945-37,182-19,142
Net Cash Growth
------
Net Cash Per Share
87.4579.07-83.85335.15-1393.08-726.73

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1,343-283.76-3,0377,992-10,9983,097
Capital Expenditures
---1,166-312.07-1,708-587.15
Free Cash Flow
-1,343-283.76-4,2037,680-12,7062,510
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
37.09%56.74%67.24%55.30%56.48%24.96%
Operating Margin
-39.01%-31.24%-49.34%-29.03%-21.26%-4.26%
Pretax Margin
-517.15%-257.94%-65.48%-56.50%-62.48%-24.36%
Profit Margin
-517.91%-257.89%-64.81%-0.61%-61.73%-23.94%
FCF Margin
-43.46%-4.36%-47.74%31.31%-56.41%2.97%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
---5.85-46.44
PS Ratio
24.572.252.361.832.471.38